Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | EVP, Head of R&D | March 02, 2023 | March 06, 2023 |
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Director | June 10, 2026 | June 11, 2026 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Chief Medical Officer | February 14, 2020 | February 19, 2020 |
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | SVP & Chief Medical Officer | October 09, 2016 | October 11, 2016 |
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Director | August 20, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 290,794 |
Reported balance
After 2023-03-02 transaction · row 1
1 source rowRow 1 · 2023-03-02 · Sale · Disposed 5,074 · Balance 290,794 F1: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.
Bolt Biotherapeutics, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2036-06-09 | Direct | 5,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 5,000 · Balance 5,000 F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
Gossamer Bio, Inc.
Report date February 14, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,500 |
Reported balance
After 2020-02-14 transaction · row 1
1 source rowRow 1 · 2020-02-14 · Grant · Acquired 46,500 · Balance 46,500 F1: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.55 · Expires 2030-02-14 | Direct | 71,500 |
Reported balance
After 2020-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-14 · Grant · Acquired 71,500 · Balance 71,500 F2: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date.
F2: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
OncoMed Pharmaceuticals Inc
Report date October 09, 2016 · Filed October 11, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,440 |
Reported balance
After 2016-10-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-10-09 · Grant · Acquired 12,500 · Balance 34,440 F1: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2: Includes 27,500 restricted stock units and 1,298 shares acquired under the Issuer's Employee Stock Purchase Plan on February 29, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof.
F2: Includes 27,500 restricted stock units and 1,298 shares acquired under the Issuer's Employee Stock Purchase Plan on February 29, 2016.
Pyxis Oncology, Inc.
Report date August 20, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.12 · Expires 2036-08-20 | Direct | 46,000 |
Reported balance
After 2026-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-20 · Grant · Acquired 46,000 · Balance 46,000 F1: The shares subject to this option will vest in equal monthly installments through October 31, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest in equal monthly installments through October 31, 2026, subject to the reporting person's continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apexigen, Inc.
Report date August 23, 2023 · Filed August 25, 2023
Section 16 reporting ended · disclosed 2023-08-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2030-09-01 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-23 · Disposition to issuer · Disposed 34,084 · Balance 0 F1: The shares subject to the option vest in 48 equal monthly installments beginning on September 10, 2020. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2031-02-12 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-23 · Disposition to issuer · Disposed 20,489 · Balance 0 F2: This exercise price was reported incorrectly as $4.49 in a Form 3/A filed on August 24, 2023. F3: The shares subject to the option vest upon the achievement of certain performance metrics. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,534 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2032-09-29 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-23 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in 48 equal monthly installments beginning on September 10, 2020. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
F2: This exercise price was reported incorrectly as $4.49 in a Form 3/A filed on August 24, 2023.
F3: The shares subject to the option vest upon the achievement of certain performance metrics. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,534 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
F4: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2021 Filed Nov 4, 2021 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,000 | $9.58 | $47,900.00 |
DisclosureSEC source: 0001567619-21-019331 · doc1.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 23:32 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,152 | $12.53 | $26,968.86 |
DisclosureSEC source: 0001567619-21-016145 · doc1.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,793 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2021 and August 18, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:32 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,184 | $14.55 | $75,427.20 |
DisclosureSEC source: 0001209191-21-034428 · doc4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,945 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2021 and May 19, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 81,327 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-21-017046 · doc4.xml · derivative · entry 2 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,327 Underlying: Common Stock · 81,327 shares Expires 2031-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2021, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 53,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017046 · doc4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,129 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2021, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| May 14, 2020 Filed May 19, 2020 23:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 277,500 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001209191-20-030712 · doc4.xml · derivative · entry 2 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,500 Underlying: Common Stock · 277,500 shares Expires 2030-05-13 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service. Read SEC document |
| May 14, 2020 Filed May 19, 2020 23:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 46,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030712 · doc4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F1 · shares: 25% of the shares subject to these restricted stock units ("RSUs") vest on May 15, 2021 and 1/16th of the total number shares subject to the RSUs vest on each of the next 12 Quarterly Vesting Dates (as defined below), subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:23 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 71,500 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-20-010521 · doc4.xml · derivative · entry 2 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2030-02-14 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:23 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 46,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010521 · doc4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 22:00 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001209191-19-062303 · doc4.xml · derivative · entry 6 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,317 Underlying: Common Stock · 40,000 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on December 14, 2018. 25% of the total number of shares subject to the option vested on December 14, 2019 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 22:00 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 40,000 | $15.00 | $600,004.00 |
DisclosureSEC source: 0001209191-19-062303 · doc4.xml · nonDerivative · entry 4 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 22:00 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Exercise / conversionCommon Stock | 40,000 | $10.71 | $428,400.00 |
DisclosureSEC source: 0001209191-19-062303 · doc4.xml · nonDerivative · entry 3 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 22:00 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative | 1,994 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001209191-19-062303 · doc4.xml · derivative · entry 5 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,317 Underlying: Common Stock · 1,994 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on December 14, 2018. 25% of the total number of shares subject to the option vested on December 14, 2019 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 22:00 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 1,994 | $15.81 | $31,534.11 |
DisclosureSEC source: 0001209191-19-062303 · doc4.xml · nonDerivative · entry 2 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 22:00 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Exercise / conversionCommon Stock | 1,994 | $10.71 | $21,355.74 |
DisclosureSEC source: 0001209191-19-062303 · doc4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 22:57 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $22.10 | $0.00 |
DisclosureSEC source: 0001209191-19-021370 · doc4.xml · derivative · entry 1 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-03-25 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 25, 2020 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
| October 09, 2016 Filed Oct 11, 2016 21:42 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-082539 · doc1.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,440 F1 · shares: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 27,500 restricted stock units and 1,298 shares acquired under the Issuer's Employee Stock Purchase Plan on February 29, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.